Affiliation:
1. Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
Abstract
Human immunodeficiency virus type 1 (HIV-1)-infected CEM cells were treated by the HIV-1-specific inhibitors bis-heteroarylpiperazine (BHAP), 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)-on e (TIBO) R82913, nevirapine, and the N3-methylthymine derivative of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO-m3T), as single agents or in combination, at escalating concentrations. When used individually, the compounds led to the emergence of drug-resistant virus strains within two to five subcultivations. The resulting strains were designated HIV-1/BHAP, HIV-1/TIBO, HIV-1/Nev, and HIV-1/TSAO-m3T, respectively. The mutant viruses showed the following amino acid substitutions in their reverse transcriptase (RT): Leu-100-->Ile for HIV-1/BHAP; Lys-103-->Asn for HIV-1/TIBO; Val-106-->Ala for HIV-1/Nev; and Glu-138-->Lys for HIV-1/TSAO-m3T. Both the Tyr-181-->Cys and Val-106-->Ala mutations were found in another mutant emerging following treatment with nevirapine at escalating concentrations. The BHAP-resistant virus remained fully sensitive to the inhibitory effects of nevirapine and TSAO-m3T, whereas the TSAO-m3T-resistant virus remained fully sensitive to the inhibitory effects of nevirapine and BHAP. When different pairs of nonnucleoside RT inhibitors (i.e., BHAP plus TSAO-m3T, nevirapine plus TSAO-m3T, TIBO plus TSAO-m3T, nevirapine plus TIBO, and BHAP plus nevirapine) were used, resistant virus emerged as fast as with single-drug therapy. In all cases the Tyr-181-->Cys mutation appeared; the virus showed markedly reduced sensitivity to all HIV-1-specific inhibitors but retained sensitivity to 2',3'-dideoxynucleoside analogs such as zidovudine, ddC, and ddI. Our findings argue against simultaneous combination of two different nonnucleoside RT inhibitors that are unable to inhibit HIV-1 mutant strains containing the Tyr-181-->Cys mutation when administered as single drugs.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference42 articles.
1. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethy1-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase;Baba M.;Proc. Natl. Acad. Sci. USA,1991
2. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative;Baba M.;Biochem. Biophys. Res. Commun.,1989
3. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase;Balzarini J.;Virology,1993
4. Balzarini J. A. Karlsson A.-M. Vandamme M.-J. Perez-Prez H. Zhang L. Vrang B. Oberg K. Backbro T. Unge A. San-F61ix S. Velazquez M.-J. Camarasa and E. De Clercq. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the novel class of HIV-1-specific TSAO nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA in press.
5. Balzarini J. A. Karlsson A.-M. Vandamme L. Vrang B. Oberg M.-J. Perez-Perez A. San-Felix S. Velizquez M.-J. Camarasa and E. De Clercq. 1992. Human immunodeficiency virus type 1 (HIV-1) strains resistant against the novel class of HIV-1-specific TSAO nucleoside analogues are sensitive to TIBO and nevirapine and the nucleoside analogues AZT DDI and DDC p. 11 Abstr. HIV Drug-Resistance Workshop.